Cargando…
Antiphospholipid syndrome
Antiphospholipid syndrome is diagnosed when arterial or venous thrombosis or recurrent miscarriages occur in a person in whom laboratory tests for antiphospholipid antibodies (anticardiolipin antibodies and/or lupus anticoagulant and/or anti-beta 2-glycoprotein I) are positive. Despite the strong as...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656223/ https://www.ncbi.nlm.nih.gov/pubmed/19090981 http://dx.doi.org/10.1186/ar2536 |
_version_ | 1782165480034795520 |
---|---|
author | Espinosa, Gerard Cervera, Ricard |
author_facet | Espinosa, Gerard Cervera, Ricard |
author_sort | Espinosa, Gerard |
collection | PubMed |
description | Antiphospholipid syndrome is diagnosed when arterial or venous thrombosis or recurrent miscarriages occur in a person in whom laboratory tests for antiphospholipid antibodies (anticardiolipin antibodies and/or lupus anticoagulant and/or anti-beta 2-glycoprotein I) are positive. Despite the strong association between antiphospho-lipid antibodies and thrombosis, their pathogenic role in the development of thrombosis has not been fully elucidated. Novel mechanisms involving both the complement pathway and micro-particles have been described. The knowledge of these new pathogenic approaches might identify novel therapeutic targets and therefore may improve the management of these patients. |
format | Text |
id | pubmed-2656223 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-26562232009-06-15 Antiphospholipid syndrome Espinosa, Gerard Cervera, Ricard Arthritis Res Ther Review Antiphospholipid syndrome is diagnosed when arterial or venous thrombosis or recurrent miscarriages occur in a person in whom laboratory tests for antiphospholipid antibodies (anticardiolipin antibodies and/or lupus anticoagulant and/or anti-beta 2-glycoprotein I) are positive. Despite the strong association between antiphospho-lipid antibodies and thrombosis, their pathogenic role in the development of thrombosis has not been fully elucidated. Novel mechanisms involving both the complement pathway and micro-particles have been described. The knowledge of these new pathogenic approaches might identify novel therapeutic targets and therefore may improve the management of these patients. BioMed Central 2008 2008-12-15 /pmc/articles/PMC2656223/ /pubmed/19090981 http://dx.doi.org/10.1186/ar2536 Text en Copyright © 2008 BioMed Central Ltd |
spellingShingle | Review Espinosa, Gerard Cervera, Ricard Antiphospholipid syndrome |
title | Antiphospholipid syndrome |
title_full | Antiphospholipid syndrome |
title_fullStr | Antiphospholipid syndrome |
title_full_unstemmed | Antiphospholipid syndrome |
title_short | Antiphospholipid syndrome |
title_sort | antiphospholipid syndrome |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656223/ https://www.ncbi.nlm.nih.gov/pubmed/19090981 http://dx.doi.org/10.1186/ar2536 |
work_keys_str_mv | AT espinosagerard antiphospholipidsyndrome AT cerveraricard antiphospholipidsyndrome |